ライフサイエンスコーパス: therapy

1 cal imaging, drug delivery, and photothermal therapy.

2 clonal selection after androgen-deprivation therapy.

3 tagonists may provide a new approach for ALD therapy.

4 l-Arginine (l-Arg) into NO for enhanced gas therapy.

5 n the primary somatosensory cortex following therapy.

6 :1) for the duration of trastuzumab adjuvant therapy.

7 s to consider AAV-mediated gene augmentation therapy.

8 e optimization and personalization of cancer therapy.

9 r expression and sensitivity to antiandrogen therapy.

10 ) are a promising candidate for a cell-based therapy.

11 atory bowel disease (IBD) receiving anti-TNF therapy.

12 molecules, for effective cancer imaging and therapy.

13 olecular phenotype which can be targeted for therapy.

14 ents regained MMR and MR4.5 after restarting therapy.

15 fer application of effective CD19 CAR T-cell therapy.

16 ms insufficiently controlled by conventional therapy.

17 mediators of resistance to immune checkpoint therapy.

18 d potentially offer an effective oral cancer therapy.

19 influence the reparative proficiency of APC therapy.

20 particularly attractive targets for antibody therapy.

21 tumor control upon treatment with anti-PD-L1 therapy.

22 ic lesions often observed in the clinic post-therapy.

23 gards to cancer understanding, diagnosis and therapy.

24 result in both effective and specific cancer therapy.

25 fic resistance mechanisms that evolve during therapy.

26 e modeling and personalized cell replacement therapy.

27 mechanical ventilation and renal-replacement therapy.

28 lternative to routine full-course antibiotic therapy.

29 PD-L1 plus olaparib or cediranib combination therapy.

30 ing de novo versus upgrade CRT defibrillator therapy.

31 metastases for tumor diagnosis, imaging, and therapy.

32 normalization of serum aminotransferases off therapy.

33 arget for molecular imaging and radionuclide therapy.

34 uld potentially be targeted as an anticancer therapy.

35 f onset, gender predominance and response to therapy.

36 sed to engineer examples of bsAbs for cancer therapy.

37 on rates as high as 40% in the first year of therapy.

38 bitors (INSTIs) as components of initial HIV therapy.

39 miting the development of targeted epigenome therapy.

40 d in the investigation of FSHD pathology and therapy.

41 ombosis despite treatment with anticoagulant therapy.

42 gy to design new approaches to antibacterial therapy.

43 in these patients to help guide decongestive therapy.

44 c features are becoming important targets of therapy.

45 ived prior potent androgen receptor-targeted therapy.

46 hout the day and in response to tuberculosis therapy.

47 cal challenges to developing successful cell therapy.

48 the Respimat device as add-on to background therapy.

49 CC patients will benefit from antiangiogenic therapy.

50 redictive of clinical response to epigenetic therapy.

51 hemodynamic and neurohormonal targets of HF therapy.

52 I domain is a potential target for antiviral therapy.

53 expression is a critical topic of endocrine therapy.

54 or for risk of worsening fibrosis during MTX therapy.

55 thways that may be exploited for neoadjuvant therapies.

56 edict which patients will benefit from these therapies.

57 fication, and select candidates for adjuvant therapies.

58 sired as high-value partners for combination therapies.

59 nts who did not respond to anti-inflammatory therapies.

60 cular mechanisms and to develop novel cancer therapies.

61 for effective prevention as important as for therapies.

62 ntial responsiveness of patients to specific therapies.

63 elevant biomarkers and trials of combination therapies.

64 d are linked to metastasis and resistance to therapies.

65 ould expedite the evaluation of new adjuvant therapies.

66 conducted prior to proceeding to combination therapies.

67 n in combination with currently approved PAH therapies.

68 used in clinical trials of disease-modifying therapies.

69 phenotype to test small-molecule Wnt agonist therapies.

70 3, 95% CI 1.59-3.12); p<0.0001), combination therapy (1.53, 1.13-2.07; p=0.054), and have their blood

71 gned (1:1) to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min

72 Compared to drug therapy, a resurgence of interest in using diet to manag

73 PD-1(+) TILs can be used in adoptive T-cell therapy (ACT).

74 Artemisinin-based combination therapies (ACTs) are the mainstay of the current treatme

75 rdance was greatest for androgen deprivation therapy (ADT) (86.0%, n = 308) alone or combined with ra

76 supports a link between androgen deprivation therapy (ADT) and cognitive dysfunction, including Alzhe

77 ubsequent dasatinib or nilotinib who stopped therapy after at least 3 years of TKI treatment and in m

78 quate attention to cardiovascular preventive therapy after diagnosis of breast cancer.

79 bate about the duration of dual antiplatelet therapy after drug-eluting stent implantation, we avoid

80 there are no large-scale clinical trials for therapies against MERS-CoV.

81 erve as a potential target for host-directed therapy aimed at manipulating host immunity against TB.

82 additional patient choice for psychological therapy, alongside CBT, for adolescents with moderate to

83 ltivariate analysis showed that echinocandin therapy altered the risk of clinical failure.

84 (Lyrica) shows clinical promise for migraine therapy, although its efficacy and mechanism of action a

85 ) during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection

86 Prevalence of long-term opioid therapy among patients with polyneuropathy and controls.

87 s to improve the efficacy of adoptive T-cell therapies and immune checkpoint therapies in myelogenous

88 tionable approach to supporting conventional therapies and overcoming GC resistance in pediatric T-AL

89 pond heterogeneously to androgen deprivation therapies and reveals characteristics of subpopulations

90 rial biofilms are recalcitrant to antibiotic therapy and a major cause of persistent and recurrent in

91 with dynamic changes in ctDNA content during therapy and a responder given a checkpoint inhibitor-bas

92 rkers to predict poor response to omalizumab therapy and alternative treatment strategies for childre

93 ilator treatments are the mainstay of asthma therapy and are used in a stepwise approach.

94 Conversely, radiation therapy and chemotherapy induce DNA damage to drive cell

95 Vss subfamilies not amplified upon anti-PD-1 therapy and could be identified by a sustained coexpress

96 Developing novel targets for SE therapy and diagnosis is important and necessary.

97 dren with persistent AA receiving omalizumab therapy and observational studies from the past 7 years

98 fied according to duration of prior systemic therapy and presence of liver metastases.

99 review the immunologic underpinnings of Treg therapy and technical challenges to developing successfu

100 mRDT also decreased the time to effective therapy and the length of stay.

101 d to help in the selection of antiretroviral therapy and to prevent virologic failure.

102 e to the development of novel antibody-based therapies, and heavy chain (Hc) heterodimers represent a

103 apies that are ineffective, modify or change therapy, and avoid disease complications.

104 uded measurable disease, failure of standard therapy, and Eastern Cooperative Oncology Group performa

105 m blockers, beta-blockers, dual antiplatelet therapy, and long-term cardiovascular events.

106 s aging population, yet no disease-modifying therapies are available.

107 Novel therapies are needed for patients with relapsed or refra

108 At present, therapies are not guided by individual risk or disease b

109 whether cancers respond to specific targeted therapies are performed increasingly often.

110 globulin, and recommendations for additional therapies are provided.

111 fferences in efficacy between antidepressant therapies are small.

112 ses, diagnostic rates and development of new therapies are still limited by a lack of knowledge of th

113 ldhood cancer treated with cranial radiation therapy are at risk for subsequent CNS tumors.

114 Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibi

115 Their frequency after antiretroviral therapy (ART) correlated with HIV viremia, CD4(+) T-cell

116 ct, Uganda, who had initiated antiretroviral therapy (ART) during chronic infection.

117 ine that could synergize with antiretroviral therapy (ART) to eliminate pediatric HIV-1 infection wil

118 a stroke soon after starting antiretroviral therapy (ART), suggesting an immune reconstitution-like

119 (C-IRIS), upon initiation of antiretroviral therapy (ART).

120 can reduce the effectiveness of conventional therapies as well as cancer immunotherapy.

121 delivery platforms of genes for vaccines or therapy, as well as more rapid development of countermea

122 in 31% of patients during the first year of therapy, associated with adverse outcome.

123 osis and CSPH who had SVR to interferon-free therapy at 6 Liver Units in Spain.

124 e investigated whether rituximab maintenance therapy at a dose of 375 mg per square meter of body-sur

125 ogic improvement 3 d after the initiation of therapy, at which time Ly6C(+) macrophages were signific

126 fy the most likely pathogen, and then choose therapy based on the results.

127 ontinued sofosbuvir-velpatasvir-voxilaprevir therapy because of an adverse event (AE).

128 ecklist, and Functional Assessment of Cancer Therapy-Bone Marrow Transplant.

129 NIC-28H1 was slightly increased at 9 d after therapy but was not seen macroscopically, indicating tha

130 n important criterion for approval of asthma therapies, but the clinical features of exacerbation-pro

131 binatorial adeno-associated viral (AAV) gene therapy by expressing DAT selectively in DA neurons and

132 butes to tumor development and resistance to therapy by suppressing BAX and its activators.

133 munotherapy.Immune checkpoint blockade (ICB) therapies can unleash anti-tumour T-cell responses.

134 fy malnourished patients so that nutritional therapy can be instituted.

135 lication of miR-146b combined with stem cell therapy could enhance regeneration of cartilaginous tiss

136 a poor prognosis, and innovative maintenance therapy could improve their outcomes.

137 ilure eligible for cardiac resynchronization therapy (CRT) either do not respond to conventional CRT

138 Oral vancomycin days of therapy decreased from an average of 13.8 days to 9.4 da

139 e the effect of low dose N-acetyl-L-cysteine therapy, delivered using a targeted, systemic, maternal,

140 Toxin-induced liver diseases lack effective therapies despite increased understanding of the role fa

141 l-CFTR subpopulation might be crucial for CF therapy development.

142 Antipyretic therapy did not reduce 28-day/hospital mortality in the

143 or human developmental biology, regenerative therapies, disease modeling, and drug discovery.

144 However, these therapies do not experience uniform uptake throughout tu

145 h infectious diseases receiving nonpreferred therapy due to severity of their reported allergy.

146 verall, 18 (22%) of 83 patients discontinued therapy due to treatment-related toxicity.

147 f the infected joint and weeks of antibiotic therapy, due to the formation of biofilm.

148 n the use of assisted ventilation and oxygen therapy during the newborn period and in lung function a

149 Since reovirus shows promise as a cancer therapy, efficient reovirus reverse genetics rescue will

150 Time to first physical therapy evaluation in the intensive care unit and the ho

151 ating biologic therapy without trying triple therapy first increases costs while providing minimal in

152 ients with atherosclerotic disease on statin therapy followed for a median of 2.2 years.

153 There are no disease-modifying therapies for either FTD or NCL, in part because of a po

154 eived antivascular endothelial growth factor therapies for neovascular AMD had decreased mortality co

155 is on the development of microbiome-targeted therapies for obesity prevention and treatment.

156 ion presents a challenge when developing new therapies for patients.

157 entions represent a novel class of potential therapies for retinal diseases, such as age-related macu

158 chemotherapy, immunosuppressive or biologic therapies for the management of rheumatologic conditions

159 into allograft rejection and lead to better therapies for transplant patients.

160 Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Eval

161 e of CBCT imaging improving the execution of therapy for both types of defects.

162 udy further supports Honokiol as a promising therapy for cancer patients receiving Dox treatment.

163 tors, can be repurposed for TSP1 replacement therapy for CCMs.

164 prevented altogether, based on the choice of therapy for FL.

165 ced an evidence-based guideline on radiation therapy for glioblastoma.

166 uction of lactoferrin to present a potential therapy for ICH.

167 iotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical be

168 Targeted therapy for neuropsychiatric disorders requires selectiv

169 anti-epidermal growth factor receptor (EGFR) therapy for oral cancer does not provide satisfactory ef

170 framework for future tailoring, triage, and therapy for patients in a more personalized and precise

171 Gene therapy for patients with this disorder is complicated b

172 of developing new PAI-1- and CCL5-targeting therapy for patients with TNBC.

173 cacy of a novel gaze-contingent music reward therapy for social anxiety disorder designed to reduce a

174 atic bacteriuria (ASB) and long durations of therapy for symptomatic urinary tract infections (UTIs),

175 implications toward developing an effective therapy for TNBC.

176 to transplantation (BTT), and as definitive therapy for toxic ingestion or idiopathic liver failure

177 esenchymal stem cells (hMSCs) is an emerging therapy for treating the failing heart.

178 nts with HIV on highly active antiretroviral therapy (HAART) had any difference in their IOP compared

179 Participants receiving insulin therapy had greater hazard of infection (hazard ratio, 2

180 without CV, patients with HCV-CV, before DAA therapy, had a lower percentage of CD4+CD25hiFoxP3+ regu

181 ytokine therapy, newer checkpoint inhibition therapies have also demonstrated activity.

182 e genetic alterations against which targeted therapies have been effective in treatment of other canc

183 rs, over 100 antisense oligonucleotide-based therapies have been tested in phase I clinical trials, a

184 search effort, clinically effective anti-RAS therapies have remained elusive, prompting a perception

185 lopments in diagnostic imaging and radiation therapy have elucidated parts of this enigma.

186 holera with oral and intravenous rehydration therapy have reduced the case fatality of cholera from m

187 Antiretroviral therapy; HIV-associated comorbidities, such as dyslipide

188 ve made great progress in their use for gene therapy; however, fundamental aspects of AAV's capsid as

189 000 population with continued use of longer therapy-ie, the short-course regimen could reduce incide

190 ptive T-cell therapies and immune checkpoint therapies in myelogenous leukemia are desired.

191 igh failure rates of artemisinin combination therapies in some areas.

192 ould be associated with initiation of statin therapy in an additional 15.8% (95% CI, 14.0%-17.5%) of

193 for selenium supplementation as an adjuvant therapy in CML.

194 re potential novel targets for host directed therapy in CNS TB.

195 lternative to blocking PAR1 for antiplatelet therapy in humans.

196 ntial benefits of combination lipid-lowering therapy in individuals with CKD are needed.

197 ced an evidence-based guideline on radiation therapy in oropharyngeal squamous cell carcinoma (OPSCC)

198 effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to m

199 cardiovascular outcomes when added to statin therapy in patients stabilized after acute coronary synd

200 als specifically designed to evaluate statin therapy in patients with cancer.

201 examined the outcomes of use of thrombolytic therapy in patients with ischemic stroke who received an

202 d safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of b

203 e clinical investigation of this combination therapy in patients with NF1 mutant melanoma.

204 for the development of a new host modulation therapy in periodontitis.

205 their vectors have shown potential for gene therapy in preclinical studies.

206 Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary In

207 ing new delivery platform for localized gene therapy in the brain.

208 We compared the relative efficacy of statin therapy in those at high genetic risk (top quintile of p

209 tion and has been responsive to immune-based therapies; in addition to early cytokine therapy, newer

210 lethal and disseminating cancer resistant to therapy, including checkpoint immunotherapies, and early

211 cancer and, ideally, the ability to monitor therapy-induced genomic changes in the tumour in an inex

212 apies that enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin

213 Future peripheral artery disease cell therapy investigational trial design may be informed by

214 Antibiotic therapy is a major risk factor for the development of di

215 recognition and discontinuation of anti-PD-1 therapy is recommended.

216 A common and serious problem with this therapy is the patient's immune response to FVIII, becau

217 Further intensification of nonspecific therapy is unlikely to offer additional benefits, becaus

218 recent years considerable progress in health therapy makes a significant improvement in natural nutra

219 g AD and/or early stage AD for which current therapies may be more beneficial.

220 Therapeutically, anti-inflammatory therapy, meibomian gland heating and expression, and scl

221 These results are consistent across therapies, methods of and times of MRD assessment, cutof

222 Replacing Nemo through gene therapy might provide therapeutic benefits.

223 Despite currently available therapies, most patients diagnosed with acute myeloid le

224 iveness to transcranial magnetic stimulation therapy (n = 154).

225 sed therapies; in addition to early cytokine therapy, newer checkpoint inhibition therapies have also

226 12D, an important genetic marker for guiding therapy of certain cancers.

227 CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins.

228 onal research as they may allow modeling and therapy of human diseases in vivo.

229 c gene editing has significant potential for therapy of neuromuscular disorders.

230 ry of messenger RNAs for protein replacement therapies offers great promise but remains challenging.

231 The effects of antiretroviral therapy on risk of severe bacterial infections in people

232 (100 mg), and ribavirin (600 mg) combination therapy or oseltamivir monotherapy twice daily for 5 day

233 nt studies have reported that anti-TNF-alpha therapy or RA itself can modulate AD pathology, although

234 Type 1 diabetes treated with insulin pump therapy or with multiple (>/=4) daily insulin injections

235 sodilation in cardiovascular homeostasis and therapy, our structural understanding of the MBS CC inte

236 Information to predict bacterial therapy outcomes was provided by pretreatment tumor size

237 or (ER(+)) and is treated with anti-estrogen therapies, particularly tamoxifen in premenopausal women

238 Although photodynamic therapy (PDT) takes advantage of the spatial-temporal co

239 ts managed with ganciclovir-based preemptive therapy (PET).

240 included use of HDCT as third-line or later therapy, platinum-refractory disease, mediastinal primar

241 isode psychosis who received social recovery therapy plus early intervention services.

242 or PSA, Gleason sum, number of prior hormone therapies, prior abiraterone or enzalutamide use, prior

243 on and maintenance regimens in first-line FL therapy published after 1990 and with sufficient data to

244 ith at least one prior irinotecan-containing therapy received labetuzumab govitecan once weekly at 8

245 Cognitive behavioral therapy reduced primary anxiety symptoms more than fluox

246 xenografts, we conclude that targeted alpha-therapy regimens may stretch beyond the realm of microme

247 g signal transduction pathways which promote therapy resistance and metastatic dissemination is the k

248 croenvironment promotes disease progression, therapy resistance and relapse.

249 Dysregulated metabolism can broadly affect therapy resistance by influencing compensatory signaling

250 IL-17A pathway in mediating pediatric severe therapy-resistant asthma (STRA).

251 h the need to identify predictive factors of therapy response.

252 In vivo alphaCD20-IL-21 therapy resulted in a significant tumor control in the r

253 LVAD therapy resulted in improvement of patient health status

254 Ammonia-lowering therapy results in improvement in skeletal muscle phenot

255 Until recently, radiation therapy (RT) was believed to mediate antineoplastic acti

256 tients, and clinical trials evaluating novel therapies should be focused on these patients.

257 are ideal cell sources for personalized cell therapies since they can be expanded to generate large n

258 ent of novel antiviral and immune modulatory therapies such that approval of new treatments can be li

259 Immune checkpoint therapies target tumor antigen-specific T cells, but les

260 ancer metabolic plasticity and design cancer therapies targeting metabolism.

261 ted for (225) Ac chelation in targeted alpha therapy (TAT).

262 may benefit more from complement-inhibiting therapy than patients with AMD in general.

263 nses to treatment, to quickly identify those therapies that are ineffective, modify or change therapy

264 The success of therapies that disrupt PD-L1-mediated tumour tolerance h

265 dvanced breast cancer, with several targeted therapies that enhance the efficacy of endocrine therapy

266 Finally, novel therapies that might restore homeostasis in the GI tract

267 in a new era of highly focused personalized therapy that may be particularly beneficial in the setti

268 Using a micelle-based nanoparticle therapy that recognizes integrin alphavbeta3 (alphavbeta

269 although some cases may respond initially to therapy, there is a high incidence of CLAD and poor surv

270 For the 20 patients who received intensive therapy, there was no difference between the proportion

271 e of death through day 30, renal-replacement therapy through day 30, perioperative myocardial infarct

272 There are currently no therapies to directly inhibit hepatic fibrosis.

273 rocesses is essential for the development of therapies to prevent or treat postoperative cognitive dy

274 evelopment with the intent of bringing novel therapies to this patient population years before PFS re

275 riable associations may help target specific therapies to those at the greatest risk of sudden and no

276 PCI]: NCT00305162; Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibi

277 ng many patients who could benefit from drug therapy to not take these drugs.

278 or intramuscular) ondansetron vs traditional therapy to resolve the symptoms of acute FPIES.

279 he foundation for prolonged ammonia-lowering therapy to reverse sarcopenia of cirrhosis.

280 cal efficacy of fosfomycin as step-down oral therapy to treat complicated urinary tract infections.

281 and the hospital, and mean days of physical therapy treatment associated with hospital length of sta

282 onal randomisation (1:1) of type of hormonal therapy used (prednisolone or tetracosactide depot).

283 and thus the outcome of liver-directed gene therapy using AAV vectors and showed in a proof-of-princ

284 Continuous renal replacement therapy using blood flow rate set at 250 mL/min was not

285 opportunities employed in combination cancer therapy using nucleic acids therapeutics for successful

286 Adaptive therapy, using patient-specific tumor dynamics to inform

287 The median previous lines of therapy was 6 (range, 3-13).

288 Short-term psychoanalytical therapy was as effective as CBT and, together with brief

289 s with AML, the response to Ara-C-containing therapy was inversely correlated with SAMHD1 expression.

290 Combination of ASA and VKA therapy was not associated with a lower risk of MI but w

291 R 51-62), median number of previous lines of therapy was two (2-5), 38 patients had high-risk cytogen

292 When compared with breast-conserving therapy, we found no significant improvement in BCSS or

293 Anti-ErbB therapies were efficient only in preclinical trials and

294 ecular factors, and patterns of postprotocol therapies were enumerated and described in long-term sur

295 Both consolidation therapies were well tolerated.

296 diagnosed with IA that received caspofungin therapy when compared with azole-treated patients.

297 to determine whether this class of potential therapies will be safe and effective for individuals wit

298 There is a need for hepatitis C virus (HCV) therapies with excellent efficacy across genotypes and i

299 nts were offered salvage radiopharmaceutical therapy with the novel NTR1 antagonist (177)Lu-3BP-227.

300 Initiating biologic therapy without trying triple therapy first increases co